Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine controlled release - Sustained Therapeutics

Next Previous
Drug Profile

Gemcitabine controlled release - Sustained Therapeutics

Alternative Names: ST-02 - Sustained Therapeutic

Latest Information Update: 28 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sustained Therapeutics
  • Developer Sustained Therapeutics; University of British Columbia
  • Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Urogenital cancer

Most Recent Events

  • 01 Apr 2024 Phase-II/III clinical trials in Urogenital cancer (Recurrent) in Canada (Intravesicular) (NCT06124976)
  • 16 Nov 2023 Sustained Therapeutics in collaboration with University of British Columbia plans a phase II/III trial for Urogenital cancer (Intravesicular) (NCT06124976)
  • 11 Oct 2023 Sustained Therapeutics plans a phase II trial for Urogenital cancer in Q4 2023 (Sustained Therapeutics pipeline, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top